ThirtyFiveBio: Ledger

Stories naming ThirtyFiveBio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
ThirtyFiveBio is not recorded as having acquired anything.

Funding announcement

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.

Brandon BioCatalyst portfolio Thu 21 Nov 2024 Brandon Capital Bristol-Myers Squibb Canaan Partners Grey Wolf Therapeutics M:M Bio Pty Ltd Pathios Therapeutics ThirtyFiveBio Vida Strategic Partners Paul G. Higham Tim Brons Dr Tom McCarthy

ThirtyFiveBio

Funding history

Investors

What ThirtyFiveBio bought

People

Coverage

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers